Tarsus Pharmaceuticals, Inc. Common Stock Earnings Dividend

Tarsus Pharmaceuticals, Inc. Common Stock’s revenue jumped 106.87% since last year same period to $162.05Mn in the Q1 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated 6.85% jump in its revenue since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s net profit jumped 72.27% since last year same period to $-6.97Mn in the Q1 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated 16.79% jump in its net profits since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 86.59% since last year same period to -4.3% in the Q1 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated 22.12% jump in its net profit margins since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.03 - a 68.3% jump from last quarter’s estimates.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.03.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 75% since last year same period to -0.16 in the Q1 2026. This indicates that the Tarsus Pharmaceuticals, Inc. Common Stock has generated 75% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tarsus Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at -0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tarsus Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at -0.14.